Fidelity Investments’s Matinas BioPharma MTNB Stock Holding History

Fidelity Investments’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Hold	0	–	-$4	–	5673
2026 Q1	–	Hold	0	–	–	–	5394
2025 Q4	–	Hold	0	–	-$9	–	5528
2025 Q3	–	Hold	0	–	–	–	5337
2025 Q2	–	Hold	0	–	–	–	5308
2025 Q1	–	Hold	0	–	–	–	5274
2024 Q2	–	Sell	-7	Closed	-$1.35K	–	5540
2024 Q1	$1.35K	Buy	7 +2	+40%	+$356	﹤0.01%	4753
2023 Q4	$757	Buy	+5	New	+$846	﹤0.01%	4781
2022 Q2	–	Sell	-10	Closed	-$6K	–	5284
2022 Q1	$6K	Buy	+10	New	+$5.52K	﹤0.01%	4386
2021 Q1	–	Hold	0	–	–	–	4341
2020 Q4	–	Hold	0	–	–	–	4135
2019 Q4	–	Sell	-2	Closed	-$1K	–	4094
2019 Q3	$1K	Buy	+2	New	+$1.08K	﹤0.01%	3653

Other funds holding MTNB

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HIW

Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

Fidelity Investments's MTNB Position: Q2 2026 in Review

Fidelity Investments held its Matinas BioPharma (MTNB) position steady in Q2 2026 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5673.

Fidelity Investments first reported a position in MTNB in Q3 2019 and has held it in 4 quarters since. The position peaked at $6K in Q1 2022. 23 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.

Fidelity Investments held 0 shares of Matinas BioPharma worth $0 as of Q2 2026.
Fidelity Investments left its Matinas BioPharma share count unchanged in Q2 2026.
Matinas BioPharma made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #5673 holding.
Fidelity Investments first reported a position in Matinas BioPharma in Q3 2019 and has held it in 4 quarters since.
Fidelity Investments's Matinas BioPharma position peaked at $6K in Q1 2022.
23 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.